Generation Bio Co. (GBIO)

NASDAQ: GBIO · IEX Real-Time Price · USD
5.41
0.27 (5.25%)
May 20, 2022 4:00 PM EDT - Market closed
Market Cap308.85M
Revenue (ttm)n/a
Net Income (ttm)-128.59M
Shares Out57.09M
EPS (ttm)-2.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume318,133
Open5.19
Previous Close5.14
Day's Range4.99 - 5.44
52-Week Range3.96 - 35.41
Betan/a
AnalystsBuy
Price Target22.70 (+319.6%)
Earnings DateMay 11, 2022

About GBIO

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

IndustryBiotechnology
IPO DateJun 12, 2020
Employees150
Stock ExchangeNASDAQ
Ticker SymbolGBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for GBIO stock is "Buy." The 12-month stock price forecast is 22.7, which is an increase of 319.59% from the latest price.

Price Target
$22.7
(319.59% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Generation Bio Co. (GBIO) Reports Q1 Loss, Lags Revenue Estimates

Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -17.31% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results

Company continues to optimize cell-targeted lipid nanoparticle (ctLNP) delivery system for nonviral genetic medicine applications in liver, retina and vaccines

2 weeks ago - GlobeNewsWire

Generation Bio to Participate in 21st Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced...

1 month ago - GlobeNewsWire

Generation Bio Co. (GBIO) Upgraded to Buy: Here's Why

Generation Bio Co. (GBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

How Much Upside is Left in Generation Bio Co. (GBIO)? Wall Street Analysts Think 505%

The consensus price target hints at a 504.9% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

1 month ago - Zacks Investment Research

Generation Bio to Participate in 42nd Annual Cowen Health Care Conference

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced...

2 months ago - GlobeNewsWire

Generation Bio Outlines 2022 Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024 Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024

2 months ago - GlobeNewsWire

Generation Bio Promotes Antoinette Paone, M.S., MBA to Chief Operating Officer

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...

3 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Generation Bio Co. - GBIO

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Generation Bio Co. ("Generation" or the "Company") (NASDAQ: GBIO). Such investors are advised to co...

4 months ago - PRNewsWire

Generation Bio to Present at 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...

4 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Robbins LLP Investigates Generation Bio Co. (GBIO) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)---- $GBIO #classaction--Generation Bio Co. (GBIO) Reports Poor Results for Preclinical Studies for Hemophilia A Program

4 months ago - Business Wire

Generation Bio Hits 52-Week Low After Preclinical Data From Hemophilia A Program

Generation Bio Co (NASDAQ: GBIO) provided an update on factor VIII expression from a series of mouse and companion non-human primate (NHP) studies in hemophilia A and an update on its development non-vi...

5 months ago - Benzinga

Generation Bio Provides Update on Preclinical Studies for Hemophilia A Program

CAMBRIDGE, MASS., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today prov...

5 months ago - GlobeNewsWire

Generation Bio Reports Business Highlights and Third Quarter 2021 Financial Results

New preclinical retinal data illustrating potential for expansive therapeutic applications of ctLNP delivery presented at ESGCT 2021 Annual Virtual Congress New preclinical retinal data illustrating pot...

6 months ago - GlobeNewsWire

Generation Bio Presents Data Demonstrating First Lipid Nanoparticle to Achieve Uniform Retinal Transduction and Toler...

Sub-retinal delivery of closed-ended DNA (ceDNA) using a retina-specific cell-targeted LNP (ctLNP) demonstrated broad photoreceptor distribution, durable expression and tolerability in rodents; potentia...

6 months ago - GlobeNewsWire

Generation Bio to Present at Jefferies Virtual Gene Therapy/Editing Summit

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...

6 months ago - GlobeNewsWire

Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress

CAMBRIDGE, Mass., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today anno...

7 months ago - GlobeNewsWire

Generation Bio Reports Business Highlights and Second Quarter 2021 Financial Results

CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported r...

9 months ago - GlobeNewsWire

Generation Bio to Present at Wedbush PacGrow Healthcare Conference 2021

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...

9 months ago - GlobeNewsWire

Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Pro...

Company to transition all portfolio programs to rapid enzymatic synthesis (RES), enabling improved quality, scale and speed of closed-ended DNA manufacturing

10 months ago - GlobeNewsWire

Generation Bio to Present at William Blair Biotech Focus Conference

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff ...

10 months ago - GlobeNewsWire

Generation Bio to Present at the JMP Securities Life Sciences Conference

CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff ...

11 months ago - GlobeNewsWire

Generation Bio to Present at the Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff M...

11 months ago - GlobeNewsWire

Generation Bio Presents Preclinical Data Demonstrating Broad Potential of Gene Therapy Platform at ASGCT and Reports ...

Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model

1 year ago - GlobeNewsWire

Generation Bio to Present at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced three digi...

1 year ago - GlobeNewsWire